These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 35131259)
1. Preferential Self-interaction of DNA Methyltransferase DNMT3A Subunits Containing the R882H Cancer Mutation Leads to Dominant Changes of Flanking Sequence Preferences. Mack A; Emperle M; Schnee P; Adam S; Pleiss J; Bashtrykov P; Jeltsch A J Mol Biol; 2022 Apr; 434(7):167482. PubMed ID: 35131259 [TBL] [Abstract][Full Text] [Related]
2. Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns. Emperle M; Adam S; Kunert S; Dukatz M; Baude A; Plass C; Rathert P; Bashtrykov P; Jeltsch A Nucleic Acids Res; 2019 Dec; 47(21):11355-11367. PubMed ID: 31620784 [TBL] [Abstract][Full Text] [Related]
4. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771 [TBL] [Abstract][Full Text] [Related]
5. DNA methyltransferase DNMT3A forms interaction networks with the CpG site and flanking sequence elements for efficient methylation. Dukatz M; Dittrich M; Stahl E; Adam S; de Mendoza A; Bashtrykov P; Jeltsch A J Biol Chem; 2022 Oct; 298(10):102462. PubMed ID: 36067881 [TBL] [Abstract][Full Text] [Related]
6. The DNMT3A R882H mutation does not cause dominant negative effects in purified mixed DNMT3A/R882H complexes. Emperle M; Dukatz M; Kunert S; Holzer K; Rajavelu A; Jurkowska RZ; Jeltsch A Sci Rep; 2018 Sep; 8(1):13242. PubMed ID: 30185810 [TBL] [Abstract][Full Text] [Related]
7. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway. Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144 [TBL] [Abstract][Full Text] [Related]
8. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis. Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683 [TBL] [Abstract][Full Text] [Related]
9. XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway. Cai X; Liu Y; Li H; Que Y; Xiao M; Wang Y; Wang X; Li D Ann Hematol; 2024 Jul; 103(7):2311-2322. PubMed ID: 38519605 [TBL] [Abstract][Full Text] [Related]
10. The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity. Nguyen TV; Yao S; Wang Y; Rolfe A; Selvaraj A; Darman R; Ke J; Warmuth M; Smith PG; Larsen NA; Yu L; Zhu P; Fekkes P; Vaillancourt FH; Bolduc DM J Biol Chem; 2019 Nov; 294(45):16966-16977. PubMed ID: 31582562 [TBL] [Abstract][Full Text] [Related]
11. Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation. Anteneh H; Fang J; Song J Nat Commun; 2020 May; 11(1):2294. PubMed ID: 32385248 [TBL] [Abstract][Full Text] [Related]
12. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia. Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761 [TBL] [Abstract][Full Text] [Related]
13. Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations. Lu J; Guo Y; Yin J; Chen J; Wang Y; Wang GG; Song J Nat Commun; 2024 Apr; 15(1):3111. PubMed ID: 38600075 [TBL] [Abstract][Full Text] [Related]
14. Effect of Tabatabaei T; Rezvany MR; Ghasemi B; Vafaei F; Zadeh MK; Zaker F; Salmaninejad A Biomed Res Int; 2024; 2024():9625043. PubMed ID: 38807916 [TBL] [Abstract][Full Text] [Related]
15. The R736H cancer mutation in DNMT3A modulates the properties of the FF-subunit interface. Kunert S; Emperle M; Adam S; Bräcker J; Brockmeyer J; Rajavelu A; Jeltsch A Biochimie; 2023 May; 208():66-74. PubMed ID: 36528185 [TBL] [Abstract][Full Text] [Related]
16. Understanding the R882H mutation effects of DNA methyltransferase DNMT3A: a combination of molecular dynamics simulations and QM/MM calculations. Liu L; Shi T; Houk KN; Zhao YL RSC Adv; 2019 Oct; 9(54):31425-31434. PubMed ID: 35527972 [TBL] [Abstract][Full Text] [Related]
17. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Scheller M; Ludwig AK; Göllner S; Rohde C; Krämer S; Stäble S; Janssen M; Müller JA; He L; Bäumer N; Arnold C; Gerß J; Schönung M; Thiede C; Niederwieser C; Niederwieser D; Serve H; Berdel WE; Thiem U; Hemmerling I; Leuschner F; Plass C; Schlesner M; Zaugg J; Milsom MD; Trumpp A; Pabst C; Lipka DB; Müller-Tidow C Nat Cancer; 2021 May; 2(5):527-544. PubMed ID: 35122024 [TBL] [Abstract][Full Text] [Related]
18. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice. Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596 [TBL] [Abstract][Full Text] [Related]
19. DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming. Yang X; Wang X; Yang Y; Li Z; Chen Y; Shang S; Wang Y J Transl Med; 2023 Jul; 21(1):481. PubMed ID: 37464424 [TBL] [Abstract][Full Text] [Related]
20. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells. Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]